Project Grant R21AG087181

Award Date 6/15/24
Completion Date 5/31/26
Dollars Obligated $449K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Sarasota, FL 34243, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $423,500 to The University of Kentucky Research Foundation to examine the role of transforming growth factor-activated kinase 1 (TAK1) in tau pathology following repetitive mild traumatic brain injury (TBI). The research aims to determine an optimal dosage and treatment regimen for the novel small molecule therapeutic BNC-1 to reduce TAK1 phosphorylation and tau pathology, neurodegeneration, and...
This $3,109,079 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research at the University of California, Riverside to investigate the role of traumatic brain injury (TBI) across the lifespan in the development of Alzheimer's disease and related dementias (ADRD). The project will use a closed head injury (CHI) TBI mouse model to examine how ADRD risk factors, such as the APOE4 gene and amyloid-beta, interact with TBI at different life stages...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), provides $487,574 in funding to investigate the role of reactive astrocytes in the propagation and clearance of tau protein in Alzheimer's disease. The key objectives are to: Determine if astrocyte GFAP (glial fibrillary acidic protein) upregulation can attenuate the trans-synaptic neuron-to-neuron propagation of...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $4,619,796 to Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to investigate the use of pulsed laser therapy as a potential treatment for traumatic brain injury (TBI)-accelerated Alzheimer's disease (AD) progression. The key research aims are to: 1) determine the impact of pulsed laser therapy on TBI-accelerated AD pathogenesis in an AD rat model and...
The National Institutes of Health's National Institute on Aging awarded a $2,366,184 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital, to support research into the mechanisms of circadian and synaptic dysfunction after repetitive mild traumatic brain injury. The three-year award, made on June 1, 2022 under the Aging Research program (CFDA 93.866), will fund work by Drs. Whalen and Lipton to define how interleukin-1 receptor 1-mediated...
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on elucidating the role of metabolic regulation and AMPK activation in modulating neutrophil extracellular traps (NETs) formation and inflammation following traumatic brain injury (TBI). The $453,860 award, with a period of performance from June 1, 2025 to April 30, 2030, will...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...
This $158,247 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research into the cell-specific neurodegenerative potential of mitochondria following traumatic brain injury (TBI). The project aims to study how TBI-induced disruptions in mitochondrial function contribute to the development of Alzheimer's-like neurodegeneration over time. Key objectives include determining injury-induced intracellular and extracellular alterations in...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $817,484.00 to the Trustees of Boston University (Boston University Medical Campus) to conduct research characterizing the spatial and temporal response to tau protein in chronic traumatic encephalopathy (CTE). The 5-year project will utilize the Boston University CTE Brain Bank, the world's largest CTE brain tissue repository, to profile cellular and molecular changes associated with CTE...

ABERRANT PTEN SIGNALING IN CHRONICALLY ACTIVATED MICROGLIA DRIVES TAU PATHOLOGY, NEURODEGENERATION AND COGNITIVE DECLINE FOLLOWING REPETITIVE BRAIN INJURY - REPETITIVE MILD TBI (R-MTBI) CAN INDUCE NEUROLOGICAL IMPAIRMENT YEARS AFTER INJURY, INCREASING THE RISK FOR ALZHEIMER'S DISEASE (AD). NO SUITABLE TREATMENTS HAVE BEEN DEVELOPED TO RESCUE THE LONG-TERM CONSEQUENCES OF TBI. ADVANCING OUR UNDERSTANDING OF THE MECHANISMS DRIVING THE CHRONIC EFFECTS OF R-MTBI IS CRITICAL, AS THIS COULD LEAD TO THE IDENTIFICATION OF NOVEL THERAPIES. MICROGLIA MEDIATED NEUROINFLAMMATION IS A COMMON FEATURE OF TBI AND AD. EXPERIMENTAL EVIDENCE SUGGESTS THAT NEURODEGENERATION AND COGNITIVE DEFICITS ARE ASSOCIATED WITH THE MALADAPTIVE TRANSFORMATION OF MICROGLIA FROM AN EARLY NEURORESTORATIVE PHENOTYPE TO A DYSFUNCTIONAL AND CHRONICALLY ACTIVATED PROINFLAMMATORY STATE. FACTORS GOVERNING THE PERSISTENCE OF THESE NEUROINFLAMMATORY RESPONSES IN THE CHRONIC SEQUELAE OF TBI REMAIN ELUSIVE. WE HAVE ESTABLISHED A WT MOUSE MODEL THAT RECAPITULATES MANY OF THE FEATURES OF HUMAN R-MTBI AND THUS REPRESENTS A TRANSLATIONALLY RELEVANT PRECLINICAL PLATFORM TO INTERROGATE THESE FACTORS. HAVING ESTABLISHED THIS R-MTBI MODEL (AND GIVEN THE ROLE OF TAU AS A PATHOGNOMONIC LESION OF TBI), WE GENERATED MICROGLIAL TRANSCRIPTOMIC PROFILES IN HUMAN TAU KNOCK IN (TAUKI) MICE AT A RANGE OF TIMEPOINTS POST-INJURY. FIRSTLY, WHEN WE COMPARED MICROGLIAL RESPONSES IN TAUKI VS WT MICE, WE REVEALED AN INCREASE IN SIGNIFICANT GENE TRANSCRIPTS BETWEEN R-MTBI AND SHAM MICROGLIA BY 3 TO 9-FOLD AT CHRONIC TIMEPOINTS. IN THE TAUKI MODEL, WE REVEAL DEFICITS IN BIOENERGETICS, CYTOKINE SIGNALING, LIPID METABOLISM, AND A PRO- INFLAMMATORY SIGNATURE OF CHRONICALLY ACTIVATED MICROGLIA, WHICH APPEAR TO BE INFLUENCED BY THE ACTIVATION OF PHOSPHATASE AND TENSIN HOMOLOG (PTEN) SIGNALING, AND THIS CORRELATED WITH TBI DEPENDENT TAU PATHOLOGY. PTEN IS A LIPID PHOSPHATASE THAT ANTAGONIZES PI3K SIGNALING, A CRITICAL NODE VITAL FOR REGULATING CELL SURVIVAL, ENERGY BIOENERGETICS AND INFLAMMATION. PTEN IS HIGHLY EXPRESSED IN MYELOID CELLS, AND ITS DYSREGULATION CAN TRIGGER THE ACTIVATION OF NEUROINFLAMMATORY RESPONSES. PTEN ACTIVATION HAS BEEN REPORTED TO OCCUR EARLY IN TAUOPATHY MODELS, AND ITS INHIBITION, DAMPENS MICROGLIAL ACTIVATION, REDUCES SYNAPTIC PHAGOCYTOSIS BY MICROGLIA, AND PRESERVES NEURONAL INTEGRITY. WE THUS HYPOTHESIZE THAT PTEN ACTIVATION IS A MEDIATOR OF CHRONICALLY ACTIVATED MICROGLIA AND THEIR DYSFUNCTIONAL ACTIVITIES, AND A DRIVER OF TAU SEEDING AND PATHOGENESIS, SUCH THAT GENETIC DELETION OF PTEN IN MICROGLIA WILL MITIGATE THE DELETERIOUS EFFECTS OF CHRONIC MICROGLIAL ACTIVATION ON TAU PATHOLOGY AND LONG-TERM TBI OUTCOMES. TO BEGIN TO ADDRESS THIS, WE DEVELOPED A CRE-LOXP MODEL THAT SPECIFICALLY DELETES PTEN IN MYELOID CELLS BETWEEN 2.5 TO 3.5 MO POST- INJURY AND REVEALED RESCUE OF PRO-INFLAMMATORY MICROGLIAL RESPONSES AFTER R-MTBI. IN THIS NEW PROPOSAL, WE PLAN TO EXPAND ON THIS WORK, USING AN IMPROVED TAMOXIFEN INDUCIBLE MODEL ON A HUMAN TAUKI BACKGROUND THAT DELETES PTEN SIGNALING IN MICROGLIA, AND NOT OTHER MYELOID CELLS. WE WILL EXPLORE THE OPTIMAL TIME-WINDOW OF INTERVENTION (EARLY VS DELAYED) AND GENERATE A DETAILED LONGITUDINAL TIME-COURSE OF NEUROBEHAVIOR, MICROGLIAL PHENOTYPE AND FUNCTION, TAU SEEDING/PATHOGENESIS AND NEUROPATHOLOGICAL OUTCOMES AFTER R-MTBI. WE WILL ALSO USE A SINGLE CELL RNASEQ MINING APPROACH TO COMPARE TBI-DEPENDENT RESPONSES IN THE PRESENCE OR ABSENCE OF PTEN DELETION TO IDENTIFY THE DISTINCTIVE STATES OF MICROGLIA AND REPARATIVE MECHANISMS THAT DRIVES THEIR FAVORABLE OUTCOMES. OUR GOAL IS TO IDENTIFY MOLECULAR MECHANISMS DRIVING THE TRANSFORMATION OF CHRONIC MICROGLIA INTO A PROINFLAMMATORY AND NEUROTOXIC PHENOTYPE THAT CONTRIBUTE TO TAUOPATHY, NEURODEGENERATION AND COGNITIVE DEFICITS, IN ORDER TO DEVELOP NEW AND EFFECTIVE DELAYED THERAPEUTIC INTERVENTIONS FOR TBI AND AD.

Posted 6/14/24, 12:00 AM